From: Antibody–drug conjugates in solid tumors: a look into novel targets
Target | Payload | Linker | DAR | Indications | |
---|---|---|---|---|---|
Trastuzumab emtansine (T-DM1) | HER2 | Maytansine (microtubule inhibitor) | Non-cleavable thioether linker | 3.5 | HER2-positive mBC pretreated with trastuzumab and a taxane; HER2-positive early BC with residual disease after neoadjuvant trastuzumab and taxanes |
Trastuzumab deruxtecan (T-DXd) | HER2 | Deruxtecan (topoisomerase inhibitor) | Protease-cleavable linker | 8 | HER2-positive mBC progressing to two or more prior anti-HER2-based regimens in the metastatic setting |
Enfortumab vedotin (EV) | Nectin-4 | Monomethyl auristatin E (microtubule inhibitor) | Protease-cleavable linker | 3.8 | Locally advanced/metastatic UC previously treated with a PD-(L)1 and a platinum-based chemotherapy in the (neo)adjuvant or metastatic setting |
Sacituzumab govitecan (SG) | Trop-2 | SN-38 (topoisomerase inhibitor) | Hydrolysable linker | 7.5 | Triple-negative mBC (who have received at least two prior therapies for metastatic disease) |